文献速递精神分裂症与精神病性障碍物质与行为成瘾

大麻使用与精神病谱系中的谷氨酸:7T质子磁共振波谱的体内证据

Cannabis use and glutamate across the psychosis spectrum: in vivo evidence from 7T proton magnetic resonance spectroscopy.
PubMed 文献 · Mol Psychiatry · 2026-06-27

发现前扣带回谷氨酸降低与大麻使用均独立关联正性和阴性精神病症状,且谷氨酸降低与正性症状的关联仅见于大麻使用者。提示前扣带回谷氨酸功能障碍可能是大麻相关症状负担的跨诊断相关因素。

要点

  • 前扣带回谷氨酸降低与大麻使用独立关联精神病谱系正性和阴性症状。
  • 谷氨酸降低与正性症状的关联仅见于大麻使用者,非使用者中未观察到此关联。
  • 精神病患者尤其大麻使用者前扣带回谷氨酸更低,提示大麻暴露与谷氨酸功能障碍相关。

核心结论

  • 前扣带回谷氨酸功能障碍可能是精神病谱系中症状负担的跨诊断相关因素,尤其在大麻使用的精神病患者中。

研究设计与样本

  • 采用线性模型评估前扣带回谷氨酸与大麻使用对精神病理症状的主效应和交互效应。

主要发现

  • 自我报告的大麻使用与尿液毒理学一致性良好,在频繁使用者中一致性最强。
  • 前扣带回谷氨酸降低和大麻使用较高均独立关联正性和阴性精神病症状。
  • 前扣带回谷氨酸降低与正性症状较高相关仅见于大麻使用者,非使用者中未观察到此关联。
  • 探索性分析提示抑郁和躁狂症状存在交互作用,谷氨酸异常可能放大大麻相关症状的整体严重度。
  • 敏感性分析显示精神病患者尤其大麻使用者前扣带回谷氨酸更低,突出诊断组差异并强化大麻暴露与谷氨酸功能障碍的联系。

临床怎么用

  • 在精神病谱系评估中,可关注大麻使用状况并结合前扣带回谷氨酸相关指标理解症状负担。
  • 对使用大麻的精神病患者,谷氨酸靶向干预可能值得进一步研究,但需纵向设计验证因果通路。

局限性

  • 原文未报告研究设计类型、样本量以外的统计细节及因果推断的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cannabis use is linked to elevated psychosis risk, yet the neurobiological mechanisms that couple use to symptom expression remain unclear. Because glutamatergic dysregulation has been implicated in both cannabis effects and psychosis vulnerability, we examined whether brain glutamate relates to dimensional psychosis symptoms as a function of cannabis use across the psychosis spectrum. Seventy-nine participants-typically developing controls, clinical high-risk individuals, and patients with psychosis-completed dimensional clinical assessments, detailed cannabis use surveys, urine toxicology, and ultra-high-field 7T magnetic resonance spectroscopy (1HMRS) of the anterior cingulate cortex (ACC). Linear models assessed the main and interactive effects of ACC glutamate and cannabis use on psychopathology symptoms. Self-reported cannabis use showed good concordance with urine toxicology, with strongest agreement among frequent users. Both lower ACC glutamate and higher cannabis use were independently associated with positive and negative psychosis symptoms. Notably, lower glutamate levels were associated with higher positive symptoms in cannabis users but not cannabis non-users. Exploratory analyses suggested interactions for depressive and manic symptoms, indicating that glutamatergic abnormalities may amplify the overall severity of cannabis-related symptoms. Sensitivity analyses revealed lower ACC glutamate in psychosis patients-especially cannabis users-highlighting diagnostic group differences and reinforcing the link between cannabis exposure and glutamatergic dysfunction. These findings implicate ACC glutamatergic dysfunction as a transdiagnostic correlate of symptom burden, particularly in those with psychosis who are cannabis users. Glutamate-targeted interventions and longitudinal designs will be needed to examine causal pathways linking cannabis exposure to psychosis-relevant outcomes.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Roalf DR, Moore TM, Stifelman J, et al. Cannabis use and glutamate across the psychosis spectrum: in vivo evidence from 7T proton magnetic resonance spectroscopy. Mol Psychiatry. 2026. PMID: 42374128. doi:10.1038/s41380-026-03705-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。